Alzinova AB (publ) (STO:ALZ)
0.4950
-0.0250 (-4.81%)
Jul 3, 2026, 5:29 PM CET
Alzinova AB Earnings Call Transcripts
Fiscal Year 2025
-
Alzheimer's disease is a growing global challenge, and a new vaccine candidate aims to offer a cost-effective, safe, and convenient alternative to current treatments. Early clinical data show promising safety and efficacy, with a Phase 2 trial and regulatory milestones underway.